Radiolabeled somatostatin receptor (SSTR) antagonists have shown in vivo higher uptake
in SSTR-expressing tumors than agonists. In this preclinical study, the SSTR2 antagonist …

Preclinical and clinical studies have indicated that somatostatin receptor (sst)–expressing
tumors demonstrate higher uptake of radiolabeled sst antagonists than of sst agonists. In 4 …

Peptide receptor scintigraphy and peptide receptor radionuclide therapy using radiolabeled
somatostatin receptor (SSTR) agonists are successfully used in the clinic for imaging and …

Purpose Targeting of tumours positive for somatostatin receptors (sst) with radiolabelled
peptides is of interest for tumour localization, staging, therapy follow-up and targeted …

Somatostatin receptor targeting of neuroendocrine tumors using radiolabeled somatostatin
agonists is today an established method to image and treat cancer patients. However, in a …

In preclinical studies in rats we evaluated biodistribution and therapeutic effects of different
somatostatin analogs,[111In-DTPA] octreotide,[90Y-DOTA, Tyr3] octreotide and [177Lu …

The human somatostatin receptor subtype 2 (hSSTr2)–68Ga-DOTATOC reporter system has
several attractive features for potential translation to human studies. These include a low …

Radiolabeled somatostatin receptor (sstr) antagonists have shown superiority in different
preclinical and clinical settings compared with the well‐established and clinically used …

Somatostatin receptor (sstr) scintigraphy for imaging and sstr analogs for treatment have
been used for more than 20 y. An important improvement in recent years was the …

Peptide receptor-targeted radionuclide therapy of somatostatin receptor-expressing tumors
is a promising application of radiolabeled somatostatin analogs. Suitable radionuclides are …